Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?

Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Since the relapse rate of DLBCL to frontline chemoimmunotherapy and salvage autologous hematopoietic cell transplant is high, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was adopted. Given the tim...

Full description

Bibliographic Details
Main Authors: Omran Saifi, MD, Mohamed A. Kharfan-Dabaja, MD, MBA, Youssef H. Zeidan, MD, PhD, Jennifer Peterson, MD, William G. Rule, MD, Scott C. Lester, MD, Bradford S. Hoppe, MD, MPH
Format: Article
Language:English
Published: Particle Therapy Co-operative Group 2020-06-01
Series:International Journal of Particle Therapy
Subjects:
car t-cell therapy
proton therapy
bridging therapy
non-hodgkin lymphoma
Online Access:https://theijpt.org/doi/pdf/10.14338/IJPT-20-00004.1

Internet

https://theijpt.org/doi/pdf/10.14338/IJPT-20-00004.1

Similar Items